Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma, Ewing 1Rhabdomyosarcoma 1Osteosarcoma 1Neuroblastoma 1Liposarcoma 1

Interventions

Cyclophosphamide 16Temozolomide 13Vincristine 10Irinotecan 8Melphalan 7Doxorubicin 7Topotecan 6Granulocyte Colony-Stimulating Factor 6Busulfan 6fludarabine 5cabozantinib 5Etoposide 5Drug Therapy 5liposomal doxorubicin 4Sirolimus 4Ifosfamide 4Filgrastim 4regorafenib 3pegfilgrastim 3irinotecan sucrosofate 3fludarabine phosphate 3Zoledronic Acid 3Radiotherapy 3Nivolumab 3Magnetic Resonance Spectroscopy 3Gemcitabine 3Cisplatin 3Bone Marrow Transplantation 3Albumin-Bound Paclitaxel 3pegylated granulocyte colony-stimulating factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Sarcoma, Ewing × silmitasertib × Clear all
NCT06541262 2026-04-09

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
104 enrolled
CNSSarcoma

Liposarcoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡